Zenyaku Kogyo Teams With Theraclone For Influenza Antibodies
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based Zenyaku Kogyo is hoping Theraclone's I-STAR technology can kick-start the company's influenza vaccine development
You may also be interested in...
Eisai Plans R&D Structure Revamp, Hoping To Turn The Development Tide
TOKYO - Eisai CEO Haruo Naito unveiled plans to revamp the company's research and development structure in hopes of having his employees produce better results, Naito told analysts Feb. 27 in Tokyo
Daiichi Nets Novel HER-3 Antibody With U3 Acquisition
Daiichi Sankyo will acquire the privately held German biotech U3 Pharma in a €150 million ($233.9 million) deal that includes a novel HER-3 receptor antagonist partnered with Amgen
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).